Sikkerhed og reaktogenicitet blev vurderet for alle forsøgspersoner i løbet af de første 3 uger efter vaccinationen, og eventuelle alvorlige bivirkninger er registreret for cirka 3. 100 vaccinerede i løbet af seks måneders follow- up.
Safety and reactogenicity evaluations were performed for all subjects during the first 3 weeks following vaccination and SAEs have been collected for approximately 3100 vaccinees during six months of follow-up.